Johnson & Johnson (JNJ) Interest Expenses (2009 - 2026)
Johnson & Johnson (JNJ) posted Interest Expenses of $3.5 billion for Q2 2026, little changed sequentially from $3.5 billion in Q1 2026, and up 34.62% YoY from $2.6 billion in Q2 2025.
Johnson & Johnson (JNJ) Interest Expenses (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Interest Expenses for 18 years, with the latest figure at $3.5 billion in Q2 2026.
- Quarterly Interest Expenses rose 34.62% year-over-year to $3.5 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.5 billion (up 34.62% YoY) and the FY2025 annual result came in at $5.3 billion, up 138.95% from the prior year.
- Interest Expenses was little changed at $3.5 billion in Q2 2026 per JNJ's latest filing, from $3.5 billion in the prior quarter.
- Over five years, Interest Expenses peaked at $5.4 billion in Q1 2022 and troughed at -$358.0 million in Q4 2023.
- A 5-year average of $2.2 billion and a median of $2.4 billion in 2023 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2022 and 2023: Interest Expenses jumped 2783.87% in 2022, then tumbled 367.16% in 2023.
- Over 5 years, Interest Expenses stood at $2.8 billion in 2022, then sank by 112.79% to -$358.0 million in 2023, then increased by 6.15% to -$336.0 million in 2024, then jumped by 463.1% to $1.2 billion in 2025, then surged by 186.89% to $3.5 billion in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $3.5 billion, $3.5 billion, and $1.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | - |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 462.00 Mn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 435.00 Mn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 673.00 Mn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 247.00 Mn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -244.19 Mn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -333.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 3.50 Bn |
| Jun 28, 2026 | 3.50 Bn |
| Mar 29, 2026 | 3.50 Bn |
| Mar 29, 2026 | 3.50 Bn |
| Dec 28, 2025 | 1.22 Bn |
| Dec 28, 2025 | 1.22 Bn |
| Sep 28, 2025 | 2.50 Bn |
| Sep 28, 2025 | 2.50 Bn |
| Jun 29, 2025 | 2.60 Bn |
| Jun 29, 2025 | 2.60 Bn |
| Mar 30, 2025 | 2.20 Bn |
| Mar 30, 2025 | 2.20 Bn |
| Dec 29, 2024 | -336.00 Mn |
| Dec 29, 2024 | -336.00 Mn |
| Sep 29, 2024 | 2.00 Bn |
| Sep 29, 2024 | 2.00 Bn |
| Jun 30, 2024 | 2.00 Bn |
| Jun 30, 2024 | 2.00 Bn |
| Mar 31, 2024 | 1.60 Bn |
| Mar 31, 2024 | 1.60 Bn |